HOME >> MEDICINE >> NEWS
Contrast agent puts new light on diagnosing breast cancer

ast tissue, making it harder to distinguish between healthy tissue and questionable masses in mammograms, Frangioni says.

The new agent works by binding to micro-calcifications produced in breast cancers. Though scientists cant explain exactly why these calcifications occur, studies show that the calcifications in malignant breast tumors contain a higher proportion of a particular calcium salt called hydroxyapatite. In benign tumors, the predominant calcium salt is calcium oxalate.

By homing in on hydroxyapatite, we can target these malignant cells with a high degree of specificity, and that has the potential to improve the patients outcome, Frangioni says.

The contrast agents are designed using a combination of bisphosphonate, a type of drug used to strengthen bone, with a near-infrared fluorophore. When used with optical tomography, an imaging method that transmits near-infrared light through the body, doctors can reconstruct a three-dimensional image of tissues deep inside the breast, highlighting areas where malignant tumors appear.

The agent also may be used during surgery to pinpoint the location of hydroxyapatite, and therefore the breast cancer cells themselves, Frangioni notes.

His group began working to develop agents to target hydroxyapatite six years ago, but efforts were stalled by the inability to manufacture large quantities of the agent.

It was a chemical catch22, he says. Bisphosphonates are insoluble in anything but water, but to prepare large quantities of the substance for our studies, we need to perform the reaction in the absence of water.

Last year, Frangionis chemistry group, led by Bhushan, went back to the drawing board and devised a scheme that allowed them to synthesize the agents sans water. Once the compound was completely assembled, the researchers found a way to then make it water soluble.

Recent studies by the lab proved that the new agent works well in
'"/>


26-Mar-2007


Page: 1 2 3

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. Targeted, oral agent Enzastaurin shows favorable results
3. Studies suggest investigational agent reduces disease activity in MS
4. Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
5. MRI contrast agent can detect heart attack in the making
6. New reagent delivers a chemical breakthrough at FSU
7. High-resolution imaging with contrast agent shows promise in osteoarthritis research
8. Study suggests anesthetic agent may have rapid antidepressant effects
9. Alzheimers medication shows promise in treating nerve agent and pesticide poisoning
10. Cranberries contain possible anti-caries/anti-plaque agents
11. New contrast agents may be on horizon for better medical imaging

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... Director of its Sienna Plantation facility. , “We are pleased to announce Dr. ... Dr. Michael (Derek) Caraway, Area Medical Director of First Choice Emergency Room – North ...
(Date:8/16/2017)... ... ... Break Every Chain”: an inspirational story for those shackled by the chains of a broken ... Shivers, a writer and a woman of great faith and wisdom. She is a ... She was born and raised in Vero Beach, Florida and has dedicated her life and ...
(Date:8/15/2017)... Buffalo, NY (PRWEB) , ... August 15, 2017 , ... ... as maintenance treatment for multiple myeloma has been completed, with the team’s findings now ... Philip L. McCarthy, MD , Director of the Blood and Marrow Transplant Program at ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading dental ... the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The Tampa ... who has shown three consecutive years of growth. For this year’s award, Progressive Dental ...
(Date:8/15/2017)... ... 2017 , ... Dr. Timothy Davis is now administering two ... This information can be used to develop patient-specific treatment plans for periodontal disease ... tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® Labs, Inc., a subsidiary ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
Breaking Medicine Technology:
Cached News: